Showing results (961-970 of 6,669) with videos related to

Sort By:
Pageof 667
Annals of Hematology|May 1, 2014
Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosisJordi Juncà, Montse Garcia-Caro, Isabel Granada, et al.
Annals of Hematology|May 1, 2014
Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemiaTohru Fujiwara, Noriko Fukuhara, Ryo Funayama, et al.
Annals of Hematology|April 2, 2014
Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myelomaAngelo Borsarelli Carvalho Brito, Gustavo Jacob Lourenço, Gislaine Borba Oliveira, et al.
Annals of Hematology|April 8, 2014
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agentsDario Ferrero, Elena Crisà, Filippo Marmont, et al.
Annals of Hematology|March 18, 2014
Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative studyJi-Won Kim, Sung-Won Kim, Kohei Tada, et al.
Annals of Hematology|May 9, 2014
Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)Marcus Hentrich, Christian Hoffmann, Franz Mosthaf, et al.
Annals of Hematology|October 4, 2016
Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal typeJae-Cheol Jo, Misung Kim, Yunsuk Choi, et al.
Annals of Hematology|April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)R Willemze, S Suciu, P Muus, et al.
Annals of Hematology|October 14, 2016
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician surveyMaya Koren-Michowitz, Noa Lavi, Martin H Ellis, et al.
Annals of Hematology|April 23, 2014
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphomaMaria Ilaria Del Principe, Francesco Buccisano, Mariagiovanna Cefalo, et al.
Pageof 667